Endometrial Cancer Mortality Rises as Management Shifts to Molecular Subtyping

Uterine corpus cancers represent a significant outlier in modern oncology, as they are among the few malignancies in the United States characterized by both increasing incidence and rising mortality rates [1, 2]. While overall cancer death rates have declined significantly since the 1990s due to improved detection and treatment, these gains are largely absent in endometrial malignancies [1, 3]. This trend is exacerbated by profound and persistent racial disparities, as Black women experience a mortality rate more than double that of White women [1, 2]. Surgical management remains the cornerstone of initial treatment, yet the choice between open, laparoscopic, and robotic approaches must be carefully balanced against patient-specific risks such as obesity and postoperative complications [4, 5]. A new analysis now synthesizes the latest epidemiological shifts and therapeutic advancements to provide a framework for modern clinical management.